Realm Therapeutics PLC (RLM) Earns Corporate Rating from N+1 Singer

Realm Therapeutics PLC (LON:RLM)‘s stock had its “corporate” rating restated by equities research analysts at N+1 Singer in a report released on Monday.

Realm Therapeutics PLC (LON RLM) opened at 28.50 on Monday. The stock’s market capitalization is GBX 14.30 million. Realm Therapeutics PLC has a 12 month low of GBX 19.00 and a 12 month high of GBX 37.00. The stock’s 50 day moving average is GBX 30.39 and its 200-day moving average is GBX 31.56.

TRADEMARK VIOLATION WARNING: This article was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at

About Realm Therapeutics PLC

Realm Therapeutics plc, formerly PuriCore plc, is a biopharmaceutical company. The Company is focused on leveraging its immunomodulatory technology to protect and improve the health of adults and children. The Company has initiated drug development programs based on its hypochlorous acid technology. The Company is engaged in the development of small molecule therapies with potential application for the treatment of diseases in a number of therapeutic areas, and an initial focus in dermatology and ophthalmology.

Receive News & Ratings for Realm Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Realm Therapeutics PLC and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply